Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus

Lupus

Volumn 7, Issue 1, 1998, Pages 53-56

  Sugiyama, M ^a   Ogasawara, H ^b   Kaneko, H ^a   Hishikawa, T ^b   Sekigawa, I ^a   Iida, N ^a   Hashimoto, H ^b   Hirose, S ^a  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclosporine; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CASE REPORT; DRUG MONITORING; FEMALE; HUMAN; IMMUNOPATHOLOGY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; THROMBOCYTOPENIA;

EID: 0031982976     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678919660     Document Type: Article

References (31)

1. Borel JF, Kis ZL, Beveridge T. The history of the discovery and development of cyclosporine (Sandimmune). In: Merluzzi VJ, Adams J (eds) The Search for Anti-Inflammatory Drugs Birkhausr: Boston,1995; 27-63.
2. Tugwell P et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet1990; 335: 1051-1055.
3. Whitcup SM, Salvo EC Jr, Nussenblatt KB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease Am J Ophthalmol 1994; 118: 39-45.
4. Pacor ML et al. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol1994; 13: 224-227.
5. Ippoliti G et al. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. Transplant Proc1994; 26: 3117-3118.
6. Gruhn WB, Diaz Buxo JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol1987; 14: 1045-1047.
7. Lambie PB, Quismorio FP Jr. Interstitial lung disease and cryoglobulinemia in polymyositis, J Rheumatol 1991; 18: 468-469.
8. Pugh MT et al. A case of adult dermatomyositis treated with cyclosporin A. Br J Rheumatol1992; 31: 855-860.
9. Lucck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry1991; 54: 1007-1008
10. Rebuck AS et al. Cyclosporin for pulmonary sarcoidosis. Lancet1984; 1: 1174.
11. Christophers E et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol1992; 26: 86-90
12. Pei Y et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose Cyclosporine. Am J Kidney Dis1994; 23: 528-536.
13. Mahrle G et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and joint involvement J Am Acad Dermatol 1995; 32: 78-88.
14. Tokuda M et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum1994; 37: 551-558.
15. Lindholm A et al. The impact of acute rejection episodes on long-term graft Junction and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation1993; 56: 307-315.
16. Burke JF Jr et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med1994; 331: 358-363.
17. Mueller AR et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? Clin Transplant 1995; 9: 176-184.
18. Sutherland DE, Moudry-Munns KC, Gruessner A. Pancreas transplant outcome with or without biological anti-T cell therapy for induction immunosuppression with use of cyclosporine. Transplant Proc1994; 26: 2752-2755.
19. Baumgartner WA et al. Heart transplantation: the Johns Hospital experience. MD Med J1987; 36: 751-756.
20. Bacigalupo A et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood1991; 77: 1423-1428.
21. Quismorio Jr FP. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubais' Lupus Erythematosus. Williams & Wilkins: Maryland,1996; 802-805.
22. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum1990; 33: 37-46.
23. Lee S et al. Thrombocytopenia in systemic lupus erythematosus associated with cytomegalovirus infection. Scand J Rheumatol1997; 26: 69.
24. Karpatkin S. Autoimmune thrombocytopenic purpura. Semin Hematol1985; 22: 260-288.
25. Matsumura O et al. Therapeutic effect of cyclosporine in thrombocytopenia associated with autoimmune disease. Transplant Proc1988; 3: 317-322.
26. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today1992; 13: 136-142.
27. Kahan BD. Immunosuppressive agents acting upon lymphokine synthesis and signal transduction. Clin Transplant1993; 7: 113-125.
28. Irschik E et al. Cyclosporin blood levels do correlate with clinical complications. Lancet1984; 2: 692-693.
29. Ogasawara H et al. Effect of low dose cyclosporine treatment on interstitial pneumonitis associated with Sjögren's syndrome. Br J Rheumatol (in press).
30. List AF et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol1993; 11: 1652-1660.
31. Maillefert JF et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol1996; 35: 430-435.